GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paragon 28 Inc (NYSE:FNA) » Definitions » Debt-to-Equity

Paragon 28 (Paragon 28) Debt-to-Equity : 0.62 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Paragon 28 Debt-to-Equity?

Paragon 28's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.6 Mil. Paragon 28's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $109.8 Mil. Paragon 28's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $177.7 Mil. Paragon 28's debt to equity for the quarter that ended in Dec. 2023 was 0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Paragon 28's Debt-to-Equity or its related term are showing as below:

FNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04   Med: 0.3   Max: 0.74
Current: 0.62

During the past 5 years, the highest Debt-to-Equity Ratio of Paragon 28 was 0.74. The lowest was 0.04. And the median was 0.30.

FNA's Debt-to-Equity is ranked worse than
78.42% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FNA: 0.62

Paragon 28 Debt-to-Equity Historical Data

The historical data trend for Paragon 28's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paragon 28 Debt-to-Equity Chart

Paragon 28 Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
0.74 0.09 0.04 0.30 0.62

Paragon 28 Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.21 0.22 0.22 0.62

Competitive Comparison of Paragon 28's Debt-to-Equity

For the Medical Devices subindustry, Paragon 28's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paragon 28's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paragon 28's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Paragon 28's Debt-to-Equity falls into.



Paragon 28 Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Paragon 28's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Paragon 28's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paragon 28  (NYSE:FNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Paragon 28 Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Paragon 28's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Paragon 28 (Paragon 28) Business Description

Traded in Other Exchanges
Address
14445 Grasslands Drive, Englewood, CO, USA, 80112
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.
Executives
Albert Dacosta director, officer: See Remarks C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Robert S Mccormack officer: See Remarks C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Kristina Wright director C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
B. Ag Bird 10 percent owner BAHNHOFSTRASSE 7, ZUG V8 CH-6300
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Matthew Jarboe officer: Chief Commercial Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Jonathan I Friedman officer: General Counsel DENTSPLY SIRONA INC., 30-30 47TH AVENUE, SUITE 500, LONG ISLAND CITY NY 11101
Lee Rosenthal 10 percent owner C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Quentin S. Blackford director 7475 LUSK BLVD., SAN DIEGO CA 92121
Frank S. Bono officer: Chief Technology Officer 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jason Allan Edie officer: Chief Technology Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Erik E Mickelson officer: Chief Accounting Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Meghan Scanlon director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752